BridgeMD
New treatment option for Parkinson Disease
Official title Frontosubthalamic Networks in Parkinson's Disease.
ClinicalTrials.gov ID: NCT06485986
What this study is testing
- What it's testing
- The goal of this experimental study with is to understand the underlying mechanisms behind the increase in impulsivity seen in some patients that undergo deep brain stimulation of the subthalamic nucleus for Parkinson's Disease. The main questions it aims to answer are: What are the distributed network effects of deep brain stimulation to the subthalamic nucleus?
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female, aged 18 years or above.
- Diagnosed with Parkinson's disease who have required implanted STN electrodes for DBS in addition to their dopamine replacement therapy.
- Diagnosed with or without (control group) impulse control disorders since the diagnosis of Parkinson's Disease.
- Participant willing and able to sit in the MEG scanner and follow instructions.
You likely can't join if
- Patients with extreme language barrier that cannot understand the purpose or instructions of the study despite the use of an interpreter.
- Other implanted medical devices that may cause artefacts during MEG recordings.
- Participants with a history of co-morbid neurological disorders.
- Participant enrolled onto another clinical trial related to a neurological disorder (including Parkinson's disease) that may interfere with the...
- Participants who are unable to sit still in a MEG scanner for the duration of this experiment e.g. patients with chronic pain or osteoarthritis. This...
See the full eligibility criteria
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female, aged 18 years or above.
- Diagnosed with Parkinson's disease who have required implanted STN electrodes for DBS in addition to their dopamine replacement therapy.
- Diagnosed with or without (control group) impulse control disorders since the diagnosis of Parkinson's Disease.
- Participant willing and able to sit in the MEG scanner and follow instructions.
- Participant willing and able to delay their morning dose of dopamine replacement therapy for up to four hours (180 minutes experimental time + journey time).
- Patients with extreme language barrier that cannot understand the purpose or instructions of the study despite the use of an interpreter.
- Other implanted medical devices that may cause artefacts during MEG recordings.
- Participants with a history of co-morbid neurological disorders.
- Participant enrolled onto another clinical trial related to a neurological disorder (including Parkinson's disease) that may interfere with the results of this study.
- Participants who are unable to sit still in a MEG scanner for the duration of this experiment e.g. patients with chronic pain or osteoarthritis. This will be assessed with their primary clinician
The study team makes the final eligibility decision.
Where it's taking place
- Oxford, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Oxford, United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.